Spero Therapeutics is trading at $1.09 (6% down) in pre-market, continuing a week-long slide after multiple prior sessions of sharp declines.
- The move appears to be driven by ongoing negative momentum rather than a new catalyst, as the stock extends its recent downward trend.
- There is no fresh company-specific news, earnings reports, or major FDA/regulatory headlines released so far this morning.